logo-loader

LeanLife Health poised for production at new plant once permits are in place

Last updated: 08:25 22 Aug 2018 EDT, First published: 03:25 22 Aug 2018 EDT

1534940807_rsz_shutterstock_130327115
Products will include ingredients for making and/or fortifying commercial foods

LeanLife Health Inc. (CSE:LLP) updated on its manufacturing capability, revealing that main equipment had been purchased and delivered to the new facility in Canada.

It is still awaiting the approval of permits to operate, but once in place will begin production immediately.

READ: LeanLife hires food safety consultants to help ensure omega-3 products meet food safety requirements

The group's products are extracted from flaxseeds, a plentiful and non-animal source of omega-3.

Such products will include ingredients for making and/or fortifying commercial foods such as bread, noodles, juices, yogurt and cheese.

The firm said that previously manufacturing was by way of a batch system, which was expensive, problematic and outdated.

"The company has acquired a continuous process manufacturing system bringing efficiency, computer monitoring and control with remote consultancy quality readout," it said in Wednesday’s regulatory statement.

"Moreover, the main manufacturing unit is scalable, with features of additional units added vertically and/or adjacently.

"In this way additional production can be added in the same location or new locations in Canada or other countries in a very efficient manner. It is also possible to have a dedicated line for a single customer enabling customer features or monitoring," it added.

READ: LeanLife Health receives processing and manufacturing equipment for production facility in Vancouver

LeanLife has also begun the process of obtaining federal government certifications in Canada and the United States.

As revealed in June, it hired external consultants to help to ensure that all of its omega-3 products meet relevant food safety requirements and designations in Canada and the US.

"The company has initial orders to fill, and inventory levels must be maintained to ensure that future order levels can also be filled," it added.

The total cost for manufacturing and lab equipment including associated costs is about C$700,000.

LeanLife Health shares are at C$0.065 in Toronto - down around 7%.

Novo Resources sees substantial upside potential at Nunyerry

Novo Resources Corp (TSX:NVO, OTCQX:NSRPF, ASX:NVO) co-chair and acting CEO Mike Spreadborough joins Jonathan Jackson in the Proactive studio to discuss promising gold outcomes from recent reanalysis of drill intercepts in a 2023 program at Nunyerry North in Western Australia. Using advanced...

8 hours, 8 minutes ago